03 June 2025 : Database Analysis
Benefits of Sodium-Glucose Cotransporter-2 Inhibitors with Renin-Angiotensin System Blockers in Type-2 Diabetes: A Cohort Analysis
Ming-Hsien Tsai ADE 1, Mingchih Chen
CD 2, Yen-Chun Huang C 3, Wei-Shan Chang C 4, Kai-Yuan Hsiao C 4, Hung-Hsiang Liou A 5, Yu-Wei Fang AEF 6*
DOI: 10.12659/MSM.947153
Med Sci Monit 2025; 31:e947153
Figure 2 Kaplan-Meier cumulative event-free plots. Comparison of (A) acute kidney injury, (B) chronic kidney disease, (C) advanced kidney failure, and (D) initialization of long-term dialysis between SGLT2i and DPP4i users with renin-angiotensin system blocker use. SGLT2i – sodium-glucose cotransporter 2 inhibitors; DDP4i – dipeptidyl peptidase-4 inhibitor.